Lupin has allotted 36979 fully paid-up equity shares of Rs 2/- each. These shares have been allotted upon exercising of vested options granted to the employees under Stock Option plans of the Company. In view of the above, the issued and paid-up share capital of the Company has been increased to Rs 91,24,69,084 consisting of 45,62,34,542 equity shares of Rs 2/- each.Powered by Capital Market - Live

Emtricitabine and tenofovir alafenamide combination is used together with other medicines to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection. The said drug is the generic equivalent of Descovy Tablets of Gilead Sciences, Inc. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. This product will be manufactured at Lupin's Nagpur facility in India. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24. Shares of Lupin shed 0.13% to currently trade at Rs 2,096 on the BSE.Powered by Capital Market - Live

GIBTULIO (empagliflozin), GIBTULIO MET (empagliflozin + metformin) and AJADUO (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease. Lupin has been marketing GIBTULIO and GIBTULIO MET since 2016, and AJADUO since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Nilesh Gupta, managing director, Lupin, said, 'Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India.' Rajeev Sibal, President ' India Region Formulations, Lupin said, 'The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India.' Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24. The counter declined 1.95% to settle at Rs 2,075 on Friday, 13 December 2024Powered by Capital Market - Live

Lupin announced today the acquisition of anti-diabetes trademarks GIBTULIO', GIBTULIO MET' and AJADUO' from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO' and GIBTULIO MET' since 2016, and AJADUO' since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. GIBTULIO' (empagliflozin), GIBTULIO MET' (empagliflozin + metformin) and AJADUO' (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.Powered by Capital Market - Live

Lupin Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 2111.45, up 1.94% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.58% on the day, quoting at 24284.95. The Sensex is at 80244.25, up 1.42%. Lupin Ltd has dropped around 4.23% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has dropped around 2.89% in last one month and is currently quoting at 21962.05, up 1.07% on the day. The volume in the stock stood at 2.99 lakh shares today, compared to the daily average of 10.87 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2105.35, up 1.84% on the day. Lupin Ltd is up 69.6% in last one year as compared to a 22.1% gain in NIFTY and a 39.6% gain in the Nifty Pharma index.The PE of the stock is 31.5 based on TTM earnings ending September 24.Powered by Capital Market - Live

Lupin allots 2642 equity shares under ESOP on 19 November 2024. In view of the above, the issued and paid-up share capital of the Company has been increased to Rs 91,23,95,126 consisting of 45,61,97,563 equity shares of Rs 2/- each.Powered by Capital Market - Live

Profit before tax (PBT) jumped 67.5% YoY to Rs 1,054.9 crore in Q2 FY25. EBITDA stood at Rs 1,382.7 crore in Q2 FY25, registering the growth of 44.3% as compared with Rs 958.2 crore in Q2 FY24. EBITDA margin stood at 25.2% in Q2 FY25 as against 19.4% in Q2 FY24. Revenue from North America for Q2 FY2025 sales were Rs 1971.1 crore, up 5.6% compared to Rs 18,66.6 crore in Q2 FY2024; accounting for 36% of Lupin's global sales. U.S. Q2 FY2025 sales were $ 220 million compared to $213 million in Q2 FY2024. The company continues to maintain its leadership position as the 3 rd largest pharmaceutical player in both U.S. generics market and U.S. India formulation sales for Q2 FY2025 sales were Rs 2,009.6 crore, up 18.8 % compared to Rs 1,691.5 crore in Q2 FY2024; accounting for 37% of Lupin's global sales. India Region Formulation sales grew by 10.9 % in the quarter, as compared to Q2 FY2024. The pharma major is the 7th largest company in the Indian Pharmaceutical Market (IQVIA MAT Sept' 24). Growth markets (APAC and LATAM) registered sales of Rs 489.6 crore in Q2 FY25, up 11.8 % compared to Rs 437.8 crore in Q2 FY2024; accounting for 9% of Lupin's global sales. Europe, Middle East, and Africa (EMEA) sales for Q1 FY25 were Rs 569.3 crore, up 19.6% compared to Rs 475.9 crore in Q2 FY2024; accounting for 10 % of Lupin's global sales. Global API sales for Q2 FY2025 were Rs 294.4 crore, up 9.7 % compared to Rs 268.4 crore in Q2 FY2024; accounting for 5% of Lupin's global sales. Investment in R&D was Rs 448.1 crore (8.2% of sales) for the quarter compared to Rs 376.4 crore (7.6% of sales) for Q2 FY2024. Nilesh Gupta, managing director, Lupin, said, 'The second quarter of FY25 reflects continued strength in our business across regions. With 40% of our U.S. revenues now coming from complex generics, India back to double-digit growth and our pipeline delivering consistently, we aim to continue improving our performance aided by sustained operating efficiencies and investment in technology.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The scrip rose 0.45% to Rs 2120 on the BSE.Powered by Capital Market - Live

The headline equity benchmarks traded with moderate losses in early trade. The Nifty traded below the 24,200 level. Oil & gas, media and auto shares declined while IT, metal and consumer durables stocks advanced. At 09:30 IST, the barometer index, the S&P BSE Sensex slipped 144.64 points or 0.18% to 79,397.15. The Nifty 50 index lost 46.05 points or 0.19% to 24,153.30. In the broader market, the S&P BSE Mid-Cap index shed 0.17% and the S&P BSE Small-Cap index declined 0.50%. The market breadth was negative. On the BSE, 1,177 shares rose and 1,723 shares fell. A total of 118 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 4,888.77 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 1,786.70 crore in the Indian equity market on 7 November 2024, provisional data showed. Stocks in Spotlight: Lupin shed 0.31%. The company's consolidated net profit jumped 74.1% to Rs 852.63 crore in Q2 FY25 as compared with Rs 489.67 crore in Q2 FY24. Revenue increased 11.3% YoY to Rs 5497.01 crore in Q2 FY24. Indian Hotels rallied 3.26% after the company's consolidated net profit surged to Rs 554.58 crore during the quarter as compared with Rs 166.92 crore in Q2 FY24. Revenue jumped 27.4% to Rs 1826.12 crore in Q2 FY25. Steel Authority of India (SAIL) slipped 4.42% after the company reported 31.3% decline in consolidated net profit to Rs 897.15 crore on 17% fall in revenue to Rs 24,675.20 crore in Q2 FY25 over Q2 FY24. Numbers to Track: The yield on India's 10-year benchmark federal paper shed 0.14% to 6.898 as compared with previous close 6.908. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 84.3725, compared with its close of 84.3250 during the previous trading session. MCX Gold futures for 5 Dec 2024 settlement fell 0.07% to Rs 77,355. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.03% to 104.54. The United States 10-year bond yield lost 0.32% to to 4.328. In the commodities market, Brent crude for Jan 2025 settlement declined 40 cents or 0.53% to $75.23 a barrel. Global Markets: Most Asian shares advanced on Friday after stocks, bonds, and commodities rallied in the US following a Federal Reserve interest rate cut by 25 basis points to a range of 4.5% to 4.75% on Thursday, a move that was widely anticipated. Fed Chair Jerome Powell stated that the recent presidential election outcome would have no immediate impact on monetary policy. He emphasized that the Fed will continue to rely on a data-driven approach for future decisions, noting that inflation is cooling as expected, while economic growth remains strong. In Europe, the Bank of England cut interest rates on Thursday for only the second time since 2020 and said future reductions were likely to be gradual, seeing higher inflation and growth after the new government's first budget. The Monetary Policy Committee voted 8-1 to cut interest rates to 4.75% from 5%. Investors are now focused on China, where a legislative meeting is concluding and may result in new stimulus measures. While Trump's victory has introduced tariff concerns for China and other developing economies, optimism remains high that Chinese authorities will announce measures to counter potential trade impacts from the US. In the US, stock indices mostly gained on Thursday, extending the recent rally spurred by Trump's victory. The S&P 500 rose 0.74% to a record 5,973.10 points, and the NASDAQ Composite climbed 1.51% to reach a record 19,269.36 points. The Dow Jones Industrial Average remained flat at 43,729.34 points but stayed close to a record high. Trump's victory, coupled with a Republican majority in Congress, suggests fewer obstacles for the 47th President in enacting significant policy reforms. He is expected to pursue a looser fiscal policy, while his protectionist trade and immigration stances are anticipated to strengthen the dollar. Powered by Capital Market - Live

Securities in F&O Ban : Aditya Birla Fashion Retail (ABFRL), Granules India Result Today: Tata Motors, Ashok Leyland, MRF, Welspun Corp, Motherson Sumi, Fortis Healthcare, Aarti Industries, Metropolis Healthcare, Dreamfolks Services, Jupiter life Line Hospitals, GE Vernova T&D, India Cements, Inox India, Info Edge, Orient Cement, Piccadily Agro, Premier Energies, Puravankara, Relaxo Footwears, R Systems International (Q3), Safari Industries, ZF Commercial, Mrs. Bectors, Cholamandalam Financial, Stocks to Watch: Lupin's consolidated net profit jumped 74.1% to Rs 852.63 crore in Q2 FY25 as compared with Rs 489.67 crore in Q2 FY24. Revenue increased 11.3% YoY to Rs 5497.01 crore in Q2 FY24. Indian Hotels' consolidated net profit surged to Rs 554.58 crore during the quarter as compared with Rs 166.92 crore in Q2 FY24. Revenue jumped 27.4% to Rs 1826.12 crore in Q2 FY25. Steel Authority of India (SAIL) reported 31.3% decline in consolidated net profit to Rs 897.15 crore on 17% fall in revenue to Rs 24,675.20 crore in Q2 FY25 over Q2 FY24. Emami jumped 19.1% YoY to Rs 212.66 crore during the quarter as compared with Rs 178.50 crore in Q2 FY24. Revenue increased 3% YoY to Rs 890.59 crore in Q2 FY25. RPG Life Sciences' consolidated net profit declined 20.3% to Rs 20.61 crore in Q2 FY25 as compared with Rs 25.86 crore in Q2 FY24. Net sales increased 12.1%YoY to Rs 172.21 crore during the quarter. Rail Vikas Nigam (RVNL)'s consolidated net profit declined 27.2% to Rs 286.88 crore on 1.2% fall in net sales to Rs 4,854.95 crore in Q2 FY25 over Q2 FY24. Ircon International's consolidated net profit declined 17.9% to Rs 205.95 on 18.1% fall in net sales to Rs 2447.52 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

Net profit of Lupin rose 74.12% to Rs 852.63 crore in the quarter ended September 2024 as against Rs 489.67 crore during the previous quarter ended September 2023. Sales rose 11.29% to Rs 5497.01 crore in the quarter ended September 2024 as against Rs 4939.23 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5497.014939.23 11 OPM %24.3818.58 - PBDT1311.78877.52 49 PBT1054.86629.67 68 NP852.63489.67 74 Powered by Capital Market - Live